ref_name,rx_name,iso_name,section,assay_name,potency_type,potency,cumulative_count,potency_upper_limit,potency_lower_limit,potency_unit,date_added
Iketani22c,Nirmatrelvir,WA1,Extended data figure 4,SARS-CoV-2 recombinant,EC50,51,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:T21I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,233,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:L50F,Extended data figure 4,SARS-CoV-2 recombinant,EC50,215,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:S144A,Extended data figure 4,SARS-CoV-2 recombinant,EC50,24,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,5100,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:A173V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,88,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:P252L,Extended data figure 4,SARS-CoV-2 recombinant,EC50,297,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,278,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:T21I+S144A,Extended data figure 4,SARS-CoV-2 recombinant,EC50,478,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:T21I+E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,4230,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:T21I+A173V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,160,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:T21I+T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,168,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:L50F+E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,2700,1,50000,3.2,nM,2022-11-03
Iketani22c,Nirmatrelvir,WA1+3CLpro:T21I+A173V+T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,756,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1,Extended data figure 4,SARS-CoV-2 recombinant,EC50,13,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:T21I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,21,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:L50F,Extended data figure 4,SARS-CoV-2 recombinant,EC50,34,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:S144A,Extended data figure 4,SARS-CoV-2 recombinant,EC50,166,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,294,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:A173V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,22,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:P252L,Extended data figure 4,SARS-CoV-2 recombinant,EC50,23,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,19,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:T21I+S144A,Extended data figure 4,SARS-CoV-2 recombinant,EC50,231,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:T21I+E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,42,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:T21I+A173V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,6,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:T21I+T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,13,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:L50F+E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,46,1,50000,3.2,nM,2022-11-03
Iketani22c,Ensitrelvir,WA1+3CLpro:T21I+A173V+T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,6,1,50000,3.2,nM,2022-11-03
Iketani22c,Remdesivir,WA1,Extended data figure 4,SARS-CoV-2 recombinant,EC50,9,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:T21I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,5,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:L50F,Extended data figure 4,SARS-CoV-2 recombinant,EC50,7,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:S144A,Extended data figure 4,SARS-CoV-2 recombinant,EC50,3,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,2,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:A173V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,17,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:P252L,Extended data figure 4,SARS-CoV-2 recombinant,EC50,6,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,6,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:T21I+S144A,Extended data figure 4,SARS-CoV-2 recombinant,EC50,5,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:T21I+E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,21,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:T21I+A173V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,18,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:T21I+T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,3,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:L50F+E166V,Extended data figure 4,SARS-CoV-2 recombinant,EC50,17,1,50000,3.2,nM,2023-03-31
Iketani22c,Remdesivir,WA1+3CLpro:T21I+A173V+T304I,Extended data figure 4,SARS-CoV-2 recombinant,EC50,25,1,50000,3.2,nM,2023-03-31
